Oncologic Surveillance After Radical Nephroureterectomy for High-risk Upper Tract Urothelial Carcinoma
Alberto Martini(The University of Texas MD Anderson Cancer Center), Marco Moschini(Vita-Salute San Raffaele University), Benjamin Predere(Lyon Genou Centre Albert Trillat), Paolo Gontero(Fondazione Ricerca Molinette), Roman Herout(Technische Universität Dresden), Alberto Briganti(University College London Hospitals NHS Foundation Trust), Luigi Nocera(Istituti di Ricovero e Cura a Carattere Scientifico), Giuseppe Simone(Istituti di Ricovero e Cura a Carattere Scientifico), Daniele Raggi(Fondazione IRCCS Istituto Nazionale dei Tumori), Francesco Montorsi(Vita-Salute San Raffaele University), Morgan Rouprêt(Sorbonne Université), Agostino Mattei(Luzerner Kantonsspital), Giuseppe Fallara(Istituti di Ricovero e Cura a Carattere Scientifico), Shahrokh F. Shariat(Universitätszahnklinik Wien), Claudio Simeone(University of Brescia), Chiara Lonati(Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia), Andrea Necchi(Vita-Salute San Raffaele University), Guillaume Ploussard(Yves Rocher (France)), Francesco Soria(Medical University of Vienna), Stefania Zamboni(Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia), Wojciech Krajewski(Wroclaw Medical University)
Cited by 26
Related Papers
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
|New England Journal of Medicine|2017|3.4k
Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial
|The Lancet|2016|2.2k
Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial
|The Lancet Oncology|2017|1.8k
Gender and Bladder Cancer: A Collaborative Review of Etiology, Biology, and Outcomes
|European Urology|2015|688